The cytotoxic effects of the formulations on primary samples from AML patients with FLT3-ITD mutations both refractory/relapse FLT3-ITD+, and FLT3-ITD+ at diagnosis were examined. The gene discussed is FLT3; the disease is acute myeloid leukemia.